Literature DB >> 11360056

The hippurate ratio as an indicator of functional hepatic reserve for resection of hepatocellular carcinoma in cirrhotic patients.

A W Hemming1, S Gallinger, P D Greig, M S Cattral, B Langer, B R Taylor, Z Verjee, E Giesbrecht, Y Nakamachi, K N Furuya.   

Abstract

Predicting the ability of the cirrhotic liver to withstand resection remains a challenge for the surgeon. This study evaluates the use of the hippurate ratio, a novel assessment of glycine conjugation of para-aminobenzoic acid by the liver, as a preoperative indicator of functional hepatic reserve. Between 1998 and 2000, sixty-one cirrhotic patients were prospectively assessed for hepatic resection using the hippurate ratio, indocyanine green retention at 15 minutes (ICG R-15), and other standard measures of liver function. Twenty-six patients were excluded as candidates for resection on the basis of inadequate functional hepatic reserve. Patients excluded from resection had significantly higher ICG R-15 values (29% +/- 9% vs. 16% +/- 12%, P = 0.001), higher Child-Pugh scores (5.9 +/- 0.9 vs. 5.3 +/- 0.4, P = 0.01), and lower hippurate ratios (30% +/- 14% vs. 45% +/- 15%, P = 0.005). There was a significant correlation between the hippurate ratio and ICG R-15. Other indicators of liver function such as factor V, factor VII, albumin, bilirubin, prothrombin time, and transaminases were no different between patients who did and those who did not undergo resection. Of the 35 patients resected, there were seven (20%) who developed varying degrees of liver failure with three perioperative deaths (8.5%). Patients who had some degree of liver failure had significantly lower hippurate ratios than patients who had no liver failure (29% +/- 10% vs. 48% +/- 14%, P = 0.002). There was no difference in ICG R-15 values between patients who had liver failure and those who did not. The hippurate ratio offers information on hepatocellular reserve that is not provided by other measures of liver function and may allow better selection of cirrhotic patients for liver resection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11360056     DOI: 10.1016/s1091-255x(01)80054-8

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  29 in total

Review 1.  Current surgical management of primary hepatocellular carcinoma.

Authors:  A W Hemming; P D Greig; B Langer
Journal:  Adv Surg       Date:  1999

2.  The lidocaine (MEGX) test as an index of hepatic function: its clinical usefulness in liver surgery.

Authors:  G Ercolani; G L Grazi; R Callivà; F Pierangeli; M Cescon; A Cavallari; A Mazziotti
Journal:  Surgery       Date:  2000-04       Impact factor: 3.982

3.  An analysis of 412 cases of hepatocellular carcinoma at a Western center.

Authors:  Y Fong; R L Sun; W Jarnagin; L H Blumgart
Journal:  Ann Surg       Date:  1999-06       Impact factor: 12.969

4.  Surgical experience with hepatic colorectal metastasis.

Authors:  A L Bradley; W C Chapman; J K Wright; J W Marsh; S Geevarghese; K T Blair; C W Pinson
Journal:  Am Surg       Date:  1999-06       Impact factor: 0.688

Review 5.  Surgical therapy of hepatic colorectal metastasis.

Authors:  Y Fong; J Salo
Journal:  Semin Oncol       Date:  1999-10       Impact factor: 4.929

6.  Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival.

Authors:  L Barbara; G Benzi; S Gaiani; F Fusconi; G Zironi; S Siringo; A Rigamonti; C Barbara; W Grigioni; A Mazziotti
Journal:  Hepatology       Date:  1992-07       Impact factor: 17.425

7.  Comparison of hepatic resection and transplantation in the treatment of liver cancer.

Authors:  H Bismuth; L Chiche
Journal:  Semin Surg Oncol       Date:  1993 Jul-Aug

8.  Surgical management of hepatocellular carcinoma: resection or transplantation?

Authors:  B Philosophe; P D Greig; A W Hemming; M S Cattral; I Wanless; I Rasul; N Baxter; B R Taylor; B Langer
Journal:  J Gastrointest Surg       Date:  1998 Jan-Feb       Impact factor: 3.452

9.  Altered PABA pharmacokinetics in cystic fibrosis. Implications for bentiromide test.

Authors:  G Koren; Z Weizman; G Forstner; S M MacLeod; P R Durie
Journal:  Dig Dis Sci       Date:  1985-10       Impact factor: 3.199

10.  Evaluation of liver function tests to predict operative risk in liver surgery.

Authors:  T Zoedler; C Ebener; H Becker; H D Roeher
Journal:  HPB Surg       Date:  1995
View more
  8 in total

1.  Hepatic vein reconstruction for resection of hepatic tumors.

Authors:  Alan W Hemming; Alan I Reed; Max R Langham; Shiro Fujita; Willem J van der Werf; Richard J Howard
Journal:  Ann Surg       Date:  2002-06       Impact factor: 12.969

2.  Association of Metabolomic Change and Treatment Response in Patients with Non-Alcoholic Fatty Liver Disease.

Authors:  Kwang Seob Lee; Yongin Cho; Hongkyung Kim; Hyunkyeong Hwang; Jin Won Cho; Yong-Ho Lee; Sang-Guk Lee
Journal:  Biomedicines       Date:  2022-05-24

Review 3.  The Potential Role of Metabolomics in Drug-Induced Liver Injury (DILI) Assessment.

Authors:  Marta Moreno-Torres; Guillermo Quintás; José V Castell
Journal:  Metabolites       Date:  2022-06-19

4.  Outcomes of resection of giant hepatocellular carcinoma in a tertiary institution: does size matter?

Authors:  Yongxian Thng; Jarrod K H Tan; Iyer G Shridhar; Stephen K Y Chang; Krishnakumar Madhavan; Alfred W C Kow
Journal:  HPB (Oxford)       Date:  2015-09-03       Impact factor: 3.647

5.  Evaluation of liver parenchyma stiffness in patients with liver tumours: optimal strategy for shear wave elastography.

Authors:  Wei Zheng; Zhong-Guo Zhou; Chong-Hei Wong; Xiao-Qing Pei; Shu-Lian Zhuang; Qing Li; Min-Shan Chen; An-Hua Li; Fu-Jun Zhang
Journal:  Eur Radiol       Date:  2018-08-13       Impact factor: 5.315

Review 6.  Gut Microbiota Modulation and Fecal Transplantation: An Overview on Innovative Strategies for Hepatic Encephalopathy Treatment.

Authors:  Ramzi Hassouneh; Jasmohan S Bajaj
Journal:  J Clin Med       Date:  2021-01-18       Impact factor: 4.241

7.  Prognosis and results after resection of very large (>or=10 cm) hepatocellular carcinoma.

Authors:  Shimul A Shah; Alice C Wei; Sean P Cleary; Ilun Yang; Ian D McGilvray; Steven Gallinger; David R Grant; Paul D Greig
Journal:  J Gastrointest Surg       Date:  2007-05       Impact factor: 3.267

8.  Liver surgery in the presence of cirrhosis or steatosis: Is morbidity increased?

Authors:  Lucas McCormack; Pablo Capitanich; Emilio Quiñonez
Journal:  Patient Saf Surg       Date:  2008-04-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.